Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oleanolic acid methyl ester (OAME) is a semi-synthetic pentacyclic triterpenoid derivative of oleanolic acid, a natural compound found in various plants. It is primarily investigated for its enhanced antitumor properties compared to its parent compound. In preclinical studies, OAME has demonstrated significant growth inhibition in pancreatic cancer cell lines, such as Aspc-1, with an IC50 lower than that of oleanolic acid. Its therapeutic potential is attributed to its ability to induce apoptosis, which is associated with the inhibition of the STAT3 signaling pathway and the subsequent downregulation of anti-apoptotic proteins like Bcl-XL. While it remains a subject of academic research, it serves as a lead candidate for the development of targeted therapies for pancreatic and other cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oleanolic acid methyl ester.